MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

MDT

82.5

-0.08%↓

VEEV

215.64

-2.19%↓

A

102.36

-0.28%↓

WBA

10.88

+0.65%↑

CHE

579.57

-0.25%↓

Search

Arcus Biosciences Inc

Cerrado

SectorSalud

7.89 0.64

Resumen

Variación precio

24h

Actual

Mínimo

7.71

Máximo

7.92

Métricas clave

By Trading Economics

Ingresos

-2M

-94M

Ventas

-22M

26M

BPA

-1.03

Margen de beneficio

-361.538

Empleados

627

EBITDA

-89M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+293.4% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-255M

813M

Apertura anterior

7.25

Cierre anterior

7.89

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

100 / 385 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Arcus Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 abr 2025, 15:57 UTC

Principales Movimientos del Mercado

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

18 abr 2025, 20:42 UTC

Adquisiciones, fusiones, absorciones

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 abr 2025, 20:32 UTC

Principales Noticias

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 abr 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 abr 2025, 19:52 UTC

Charlas de Mercado

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 abr 2025, 19:40 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

18 abr 2025, 19:40 UTC

Charlas de Mercado

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 abr 2025, 18:51 UTC

Ganancias

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 abr 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 abr 2025, 18:29 UTC

Charlas de Mercado

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 abr 2025, 18:21 UTC

Principales Noticias

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 abr 2025, 17:31 UTC

Principales Noticias

Trump to Replace Acting IRS Commissioner -- WSJ

18 abr 2025, 17:24 UTC

Adquisiciones, fusiones, absorciones

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 abr 2025, 17:22 UTC

Adquisiciones, fusiones, absorciones

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 abr 2025, 16:00 UTC

Principales Noticias

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 abr 2025, 15:53 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 abr 2025, 15:46 UTC

Ganancias

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 abr 2025, 15:10 UTC

Charlas de Mercado
Ganancias

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 abr 2025, 14:46 UTC

Ganancias

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 abr 2025, 14:24 UTC

Charlas de Mercado
Ganancias

Netflix Still Has Room to Add Subscribers -- Market Talk

18 abr 2025, 14:17 UTC

Ganancias

Apple Is an Efficiency Champion. This Company Is Closing in on Its Crown. -- Barrons.com

18 abr 2025, 13:55 UTC

Principales Noticias

EU Delayed Punishing Apple, Meta Just Before Trade Talks Started -- WSJ

18 abr 2025, 11:21 UTC

Ganancias

Netflix Stock Jumps on Earnings Beat. Why Tariffs Won't Hurt the Streamer. -- Barrons.com

18 abr 2025, 11:00 UTC

Principales Noticias

Amazon's Vast Empire Gives It a Leg Up in the Trade War -- Heard on the Street -- WSJ

18 abr 2025, 11:00 UTC

Principales Noticias

Johnson & Johnson Pivots Its AI Strategy -- WSJ

18 abr 2025, 10:36 UTC

Principales Noticias

Trump Signals China's Xi Has Reached Out About a Trade Deal. Here's the Latest on Tariffs. -- Barrons.com

18 abr 2025, 10:26 UTC

Principales Noticias

Why World Leaders Are Pulling Their Punches in the Trade War -- Update

18 abr 2025, 09:30 UTC

Principales Noticias

Now Streaming on Netflix: A Show Where Profits Trump the Trade War -- Heard on the Street -- Update

18 abr 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

18 abr 2025, 06:52 UTC

Charlas de Mercado

Nikkei Rises 1.0%, Led by Pharma, Shipping Stocks -- Market Talk

Comparación entre iguales

Cambio de precio

Arcus Biosciences Inc Esperado

Precio Objetivo

By TipRanks

293.4% repunte

Estimación a 12 meses

Media 31 USD  293.4%

Máximo 46 USD

Mínimo 17 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

7.63 / 8.01Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

100 / 385 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.